MedTrace Logo

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

NCT00013663 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2012-11-02

No results posted yet for this study

Summary

The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

DRUG

Aldesleukin

Sponsors & Collaborators

  • New York Presbyterian Hospital

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Kendall A. Smith, MD · Division of Immunology, Department of Medicine, Weill Medical College, Cornell University

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00013663 on ClinicalTrials.gov